Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Phuong T. Vo, MD, Ted Gooley, PhD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Robyn Haaf, BS, Margaret E. Nartea, BS, Rainer F. Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD PhD, John M. Pagel, MD PhD, Brenda M. Sandmaier, MD

Blood (2018) 132 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2018-99-111915

Published: 2018

Journal Articles

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Sherilyn A Tuazon, MD, Brenda M. Sandmaier, MD, Johnnie J. Orozco, MD PhD, Ajay K. Gopal, MD, Leona A. Holmberg, MD PhD, Pamela S. Becker, MD PhD, Sally J. Lundberg, Brian G. Till, MD, Margaret E. Nartea, Ted Gooley, PhD, Darrell R. Fisher, PhD, Joseph G. Rajendran, MD, Oliver W. Press, MD PhD, William I. Bensinger, MD, Damian J. Green, MD

Blood (2017) 130 (Supplement 1): 910.

https://doi.org/10.1182/blood.V130.Suppl_1.910.910

Published: 2017

Journal Articles

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Blood (2017) 130 (Supplement 1): 2048.

https://doi.org/10.1182/blood.V130.Suppl_1.2048.2048

Published: 2017

Journal Articles

A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Paul S Martin, MD, Isaac C Jenkins, MS, Theodore A Gooley, PhD, Damian J Green, MD, John M Pagel, MD PhD, Sally J Lundberg, RN, Lacey M Hedine, Joseph G Rajendran, MD, Andrew T Shields, MD, Darrell R Fisher, PhD, David G Maloney, MD PhD, Frederick R Appelbaum, MD, Ryan D Cassaday, MD, Oliver W Press, MD PhD, Ajay K. Gopal, MD

Blood (2015) 126 (23): 5502.

https://doi.org/10.1182/blood.V126.23.5502.5502

Published: 2015

Journal Articles

A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Ryan D. Cassaday, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD, Joseph G. Rajendran, MD, Theodore A. Gooley, PhD, Darrell R. Fisher, PhD, Sally J. Lundberg, Lacey M. Hedin, Andrew T. Shields, MD, Damian J. Green, MD, Robert S. Miyaoka, PhD, Frederick R. Appelbaum, MD, Ajay K. Gopal, MD

Blood (2013) 122 (21): 3333.

https://doi.org/10.1182/blood.V122.21.3333.3333

Published: 2013

Journal Articles

A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Ted A. Gooley, PhD, Joseph G Rajendran, MD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, H. Joachim Deeg, MD, Andrew Shields, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 1924.

https://doi.org/10.1182/blood.V120.21.1924.1924

Published: 2012

Journal Articles

Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT

Raya Mawad, MD, Paul O'Donnell, MD, PhD, Ted A. Gooley, PhD, Joseph G Rajendran, MD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, H. Joachim Deeg, MD, Andrew Shields, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 4164.

https://doi.org/10.1182/blood.V120.21.4164.4164

Published: 2012

Journal Articles

A Phase II Trial of 90 Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).

Ajay K. Gopal, MD, Joseph G. Rajendran, MD, John M. Pagel, MD, PhD, Katherine A. Guthrie, PhD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Brenda M. Sandmaier, MD, Rainer F. Storb, MD, Oliver W. Press, MD, PhD

Blood (2006) 108 (11): 316.

https://doi.org/10.1182/blood.V108.11.316.316

Published: 2006

Journal Articles

131 I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

John M. Pagel, MD, PhD, Frederick R. Appelbaum, MD, Brenda M. Sandmaier, MD, Joseph G. Rajendran, MD, Ted Gooley, PhD, Darrell R. Fisher, PhD, Eneida Nemecek, MD, Ajay K. Gopal, MD, Michael B. Maris, MD, Katherine Ruffner, MD, Dana C. Matthews, MD, H. Joachim Deeg, MD, David G. Maloney, MD, PhD, Paul J. Martin, MD, Rainer Storb, MD

Blood (2005) 106 (11): 397.

https://doi.org/10.1182/blood.V106.11.397.397

Published: 2005

Journal Articles

A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma.

Ajay K. Gopal, MD, Joseph G. Rajendran, MD, Ted A. Gooley, PhD, John M. Pagel, MD, PhD, Darrell R. Fisher, PhD, Stephen Petersdorf, MD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Oliver W. Press, MD, PhD

Blood (2005) 106 (11): 487.

https://doi.org/10.1182/blood.V106.11.487.487

Published: 2005

Journal Articles

131 I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission.

John M. Pagel, MD, PhD, Frederick R. Appelbaum, MD, Janet F. Eary, MD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Ted Gooley, PhD, Eneida Nemecek, MD, Katherine Ruffner, MD, Eileen Sickle, RN, Larry Durack, CNMT, Jeanette Carreras, MPH, Mary M. Horowitz, MD, MS, Ajay K. Gopal, MD, Oliver W. Press, MD, PhD, Paul J. Martin, MD, Irwin D. Bernstein, MD, Dana C. Matthews, MD

Blood (2004) 104 (11): 813.

https://doi.org/10.1182/blood.V104.11.813.813

Published: 2004

Journal Articles

A Myeloablative Regimen Incorporating Radiolabeled Anti-CD45 (BC8) Antibody Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Advanced Acute Myeloid Leukemia (AML).

Eneida R. Nemecek, MD, John M. Pagel, MD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Frederick R. Appelbaum, MD, Oliver W. Press, MD, PhD, Dana C. Matthews, MD

Blood (2004) 104 (11): 828.

https://doi.org/10.1182/blood.V104.11.828.828

Published: 2004

NARROW

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma

A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

A Phase II Trial of 90 Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).

131 I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma.

131 I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission.

A Myeloablative Regimen Incorporating Radiolabeled Anti-CD45 (BC8) Antibody Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Advanced Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only